SciSparc Ltd. (SPRC)
| Market Cap | 764.92K |
| Revenue (ttm) | 1.75M |
| Net Income (ttm) | -5.68M |
| Shares Out | 3.59M |
| EPS (ttm) | -5.01 |
| PE Ratio | n/a |
| Forward PE | 0.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 602,135 |
| Open | 0.221 |
| Previous Close | 0.214 |
| Day's Range | 0.201 - 0.228 |
| 52-Week Range | 0.201 - 6.780 |
| Beta | 1.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 15, 2025 |
About SPRC
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in sof... [Read more]
Financial Performance
In 2023, SciSparc's revenue was $2.88 million, an increase of 113.73% compared to the previous year's $1.35 million. Losses were -$5.12 million, 97.6% more than in 2022.
Financial StatementsNews
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
According to the LOI , SciSparc's pharmaceuticals assets are valued at approximately US $11. 6 million
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
FDA confirm s that SciSparc's study may proceed only a month after application submission
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
The intended selling valuation represents an increase of 47 % from the valuation at the time of SciSparc's initial investment in MitoCareX Bio
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
FDA confirm s that SciSparc's study may proceed following the application submission a month ago
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer
To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t...
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center , Jerusalem , Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of...
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
Friday, SciSparc Ltd. SPRC signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program to treat pain.
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met
SciSparc Updates Regarding the Status of the AutoMax Merger
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's approval of AutoMax's petition to convene special class meetings of its shar...
SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
SciSparc will receive additional payments and execution fees if certain milestones are met
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare...
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t...
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
According to the agreement, SciSparc's pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “...
SciSparc Secures Strategic Advantage with Grant of European Patent
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to...
Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health
WASHINGTON--(BUSINESS WIRE)--New research provides resources for increasing 988 usage and access among populations disproportionately impacted by suicide and their loved ones.
SciSparc to Acquire AutoMax
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...